Research
PCMA Statement on New Milliman Report on Insulin Coverage in Medicare Part D
June 22, 2022
Understanding beneficiaries' formulary coverage for insulin products in 2020, 2021, and 2022....
Medicare Part D 2023 Proposed Rule Could Increase Costs
March 07, 2022
New Milliman Analysis Shows Medicare Part D Proposed Rule Could Increase Premiums More than It Saves in Cost Sharing for...
Drug Manufacturer Strategies for Keeping Drug Costs High
November 16, 2021
The research firm Visante examines certain drug manufacturer anti-competitive tactics that affect many different types of prescription drugs. For example,...
Understanding Differences Between The Number of Pharmacies Reported by NCPA and NCPDP
October 29, 2021
Over the last several years, it has become increasingly apparent that there is a growing data discrepancy between reports that...
Mandating Pharmacy Reimbursement Will Increase Prescription Drug Spending
August 31, 2021
A new report, Mandating Pharmacy Reimbursement Will Increase Prescription Drug Spending, examines how paying pharmacies more for dispensing medications will...
Nationwide, More Independent Pharmacies Opened in 2020
July 16, 2021
During the COVID-19 pandemic, the net number of retail independent pharmacies nationwide increased. The recent increases in the number of...
Estimated cost of potential “frozen formulary” legislation
February 02, 2021
“Frozen formulary” legislation refers to regulations proposed by state legislators that would prohibit a pharmacy benefit manager (PBM) or health...
Protected: National Online Survey of Seniors Regarding the Medicare Part D Prescription Drug Benefit
January 26, 2021
There is no excerpt because this is a protected post....
January 25, 2021
A new report, “Pharmacy Services Administrative Organizations (PSAOs) and their Little-Known Connection to Independent Pharmacies,” sheds light on the role...
January 07, 2021
A new white paper by the Pharmacy Benefit Management Institute (PBMI) outlines ways that some drug manufacturers undermine formulary and...
Impact of Medicare Part D Drug Manufacturer Rebates at the Point-of-Sale
November 18, 2020
A new report by Milliman shows that over the 10-year period 2022-2031, if all manufacturer rebates were reflected at the...
Negative Economic Impact of Restricting Drug Rebates in Medicare Part: Matrix Global Advisors
September 02, 2020
“Negative Economic Impact of Restricting Rebates in Medicare Part D,” by Alex Brill of Matrix Global Advisors (MGA), examines recent...
